An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264

Trial Profile

An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 14 Aug 2017 Planned primary completion date changed from 6 Oct 2017 to 26 Sep 2017.
    • 31 Jul 2017 Planned End Date changed from 26 Jul 2017 to 6 Oct 2017.
    • 31 Jul 2017 Planned primary completion date changed from 15 Jul 2017 to 6 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top